GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amphastar Pharmaceuticals Inc (FRA:29A) » Definitions » YoY Rev. per Sh. Growth

Amphastar Pharmaceuticals (FRA:29A) YoY Rev. per Sh. Growth : 12.69% (As of Dec. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Amphastar Pharmaceuticals YoY Rev. per Sh. Growth?

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months. Amphastar Pharmaceuticals's YoY Rev. per Sh. Growth for the quarter that ended in Dec. 2024 was 12.69%.

Amphastar Pharmaceuticals's Revenue per Share for the three months ended in Dec. 2024 was €3.47.


Amphastar Pharmaceuticals YoY Rev. per Sh. Growth Historical Data

The historical data trend for Amphastar Pharmaceuticals's YoY Rev. per Sh. Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amphastar Pharmaceuticals YoY Rev. per Sh. Growth Chart

Amphastar Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
YoY Rev. per Sh. Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.71 32.93 15.46 24.08 20.44

Amphastar Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
YoY Rev. per Sh. Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 24.99 18.52 28.54 5.86 12.69

Amphastar Pharmaceuticals YoY Rev. per Sh. Growth Calculation

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months.

Amphastar Pharmaceuticals's YoY Rev. per Sh. Growth for the fiscal year that ended in Dec. 2024 is calculated as:

YoY Rev. per Sh. Growth (A: Dec. 2024 )
=(Revenue per Share (A: Dec. 2024 )-Revenue per Share (A: Dec. 2023 ))/ | Revenue per Share (A: Dec. 2023 ) |
=(13.428-11.149)/ | 11.149 |
=20.44 %

Amphastar Pharmaceuticals's YoY Rev. per Sh. Growth for the quarter that ended in Dec. 2024 is calculated as:

YoY Rev. per Sh. Growth (Q: Dec. 2024 )
=(Revenue per Share (Q: Dec. 2024 )-Revenue per Share (Q: Dec. 2023 )) / | Revenue per Share (Q: Dec. 2023 )) |
=(3.472-3.081)/ | 3.081 |
=12.69 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Amphastar Pharmaceuticals YoY Rev. per Sh. Growth Related Terms

Thank you for viewing the detailed overview of Amphastar Pharmaceuticals's YoY Rev. per Sh. Growth provided by GuruFocus.com. Please click on the following links to see related term pages.


Amphastar Pharmaceuticals Business Description

Traded in Other Exchanges
Address
11570 6th Street, Rancho Cucamonga, CA, USA, 91730
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment pharmaceutical products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.

Amphastar Pharmaceuticals Headlines

No Headlines